Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B.

Bosc D, Vezenkov L, Bortnik S, An J, Xu J, Choutka C, Hannigan AM, Kovacic S, Loo S, Clark PGK, Chen G, Guay-Ross RN, Yang K, Dragowska WH, Zhang F, Go NE, Leung A, Honson NS, Pfeifer TA, Gleave M, Bally M, Jones SJ, Gorski SM, Young RN.

Sci Rep. 2018 Aug 3;8(1):11653. doi: 10.1038/s41598-018-29900-x.

2.

Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.

Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.

J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.

3.

Development of a copper-clioquinol formulation suitable for intravenous use.

Wehbe M, Malhotra AK, Anantha M, Lo C, Dragowska WH, Dos Santos N, Bally MB.

Drug Deliv Transl Res. 2018 Feb;8(1):239-251. doi: 10.1007/s13346-017-0455-7.

4.

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Wehbe M, Lo C, Leung AWY, Dragowska WH, Ryan GM, Bally MB.

Invest New Drugs. 2017 Dec;35(6):682-690. doi: 10.1007/s10637-017-0488-2. Epub 2017 Jul 21.

5.

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.

Wehbe M, Anantha M, Shi M, Leung AW, Dragowska WH, Sanche L, Bally MB.

Int J Nanomedicine. 2017 May 31;12:4129-4146. doi: 10.2147/IJN.S137347. eCollection 2017.

6.

In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB.

Drug Deliv Transl Res. 2017 Aug;7(4):544-557. doi: 10.1007/s13346-017-0380-9.

PMID:
28432657
7.

Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.

Bortnik S, Choutka C, Horlings HM, Leung S, Baker JH, Lebovitz C, Dragowska WH, Go NE, Bally MB, Minchinton AI, Gelmon KA, Gorski SM.

Oncotarget. 2016 Oct 11;7(41):66970-66988. doi: 10.18632/oncotarget.11408.

8.

Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT.

Sci Rep. 2016 Jan 4;6:18537. doi: 10.1038/srep18537.

9.

3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.

Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, Laskin JJ, Stirling PC, Qadir MA, Bally MB.

Oncotarget. 2015 Jul 10;6(19):17161-77.

11.

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM.

Clin Cancer Res. 2014 Jun 15;20(12):3159-73. doi: 10.1158/1078-0432.CCR-13-2060. Epub 2014 Apr 10.

12.

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.

Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, Gorski SM, Gelmon KA, Bally MB.

PLoS One. 2013 Oct 11;8(10):e76503. doi: 10.1371/journal.pone.0076503. eCollection 2013.

13.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

14.

Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, Yapp DT.

Clin Cancer Res. 2008 Nov 15;14(22):7260-71. doi: 10.1158/1078-0432.CCR-08-0736.

15.

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).

Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB.

Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.

16.

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM.

Breast Cancer Res Treat. 2008 Dec;112(3):389-403. doi: 10.1007/s10549-007-9873-4. Epub 2008 Jan 3.

PMID:
18172760
17.

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB.

Breast Cancer Res Treat. 2007 Dec;106(3):319-31. Epub 2007 Mar 9.

PMID:
17347776
18.

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.

Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB.

Mol Cancer Ther. 2007 Mar;6(3):844-55. Epub 2007 Mar 5.

19.

Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.

Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M.

BJU Int. 2007 May;99(5):1154-60. Epub 2007 Feb 19. Erratum in: BJU Int. 2007 May;99(5):1161. Fadzli, Ladan [corrected to Fazli, Ladan].

20.

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB.

Eur J Pharm Biopharm. 2007 Mar;65(3):289-99. Epub 2006 Oct 17.

PMID:
17123800
21.

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.

Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB.

Mol Cancer Ther. 2006 Mar;5(3):645-54.

22.

The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.

Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB.

Curr Drug Deliv. 2005 Oct;2(4):341-51. Review.

PMID:
16305437
23.

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S.

Oncogene. 2005 May 19;24(22):3596-605.

PMID:
15782140
24.

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.

Mol Cancer Res. 2004 Nov;2(11):606-19.

26.

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB.

Cancer Biol Ther. 2004 Feb;3(2):197-204. Epub 2004 Feb 1.

PMID:
14726684
27.

Aberrant expression of T-plastin in Sezary cells.

Su MW, Dorocicz I, Dragowska WH, Ho V, Li G, Voss N, Gascoyne R, Zhou Y.

Cancer Res. 2003 Nov 1;63(21):7122-7.

29.

Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.

Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP.

Vaccine. 2003 Jul 4;21(23):3319-29.

PMID:
12804863
30.
32.

Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.

Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH, Mayer LD.

Breast Cancer Res Treat. 2000 Oct;63(3):199-212.

PMID:
11110054
34.

A comparison of long-term repopulating hematopoietic stem cells in fetal liver and adult bone marrow from the mouse.

Rebel VI, Miller CL, Thornbury GR, Dragowska WH, Eaves CJ, Lansdorp PM.

Exp Hematol. 1996 Apr;24(5):638-48.

PMID:
8605969
35.

Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.

Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12223-7.

Supplemental Content

Loading ...
Support Center